<DOC>
	<DOCNO>NCT01385657</DOCNO>
	<brief_summary>The purpose study assess safety tolerability repeat subcutaneous ( SC ) dose REGN668 patient moderate-to-severe atopic dermatitis ( AD ) .</brief_summary>
	<brief_title>Safety Tolerability REGN668 ( SAR231893 ) Patients With Moderate Severe Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Male female , 18 year old 2 . Chronic AD diagnose Eichenfield revise criterion Hannifin Rajka present least 3 year screen visit 3 . Eczema Area Severity Index ( EASI ) score &gt; /= 12 screen baseline visit 4 . Investigator 's Global Assessment ( IGA ) score &gt; /= 3 screen baseline visit 5 . &gt; /= 10 % body surface area ( BSA ) AD involvement screen baseline visit 6 . History inadequate response stable ( &gt; /= 1 month ) regimen topical corticosteroid calcineurin inhibitor treatment AD within 3 month screen visit 1 . Positive Hepatitis B surface antigen , and/or positive Hepatitis C antibody screen visit 2 . Treatment investigational drug within 8 week within 5 halflives , know , whichever longer , baseline visit 3 . Treatment leukotriene inhibitor within 4 week baseline visit 4 . Treatment systemic corticosteroid within 4 week baseline visit 5 . Treatment topical corticosteroid , tacrolimus , and/or pimecrolimus within 1 week baseline visit 6 . Systemic treatment AD immunosuppressive/immunomodulating substance within 4 week baseline visit 7 . Chronic acute infection require treatment oral IV antibiotic , antiviral , antifungal within 4 week screen visit superficial skin infection within 1 week screen visit 8 . Known history human immunodeficiency virus ( HIV ) infection 9 . History clinical parasite infection , treat trichomoniasis 10 . History malignancy within 5 year baseline visit , follow exception : patient history completely treat carcinoma situ cervix , nonmetastatic squamous basal cell carcinoma skin allow 11 . Any medical psychiatric condition , opinion investigator sponsor 's medical monitor , would place patient risk , interfere participation study , interfere interpretation study result 12 . Pregnant breastfeed woman 13 . Unwilling use adequate birth control , reproductive potential sexually active</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>